Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?

@article{Charlier2006FluconazoleFT,
  title={Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?},
  author={Caroline Charlier and Emily Rose Hart and Agn{\`e}s Lefort and Patricia Ribaud and Françoise Dromer and David William Denning and Olivier Lortholary},
  journal={The Journal of antimicrobial chemotherapy},
  year={2006},
  volume={57 3},
  pages={384-410}
}
Candida spp. are responsible for most of the fungal infections in humans. Available since 1990, fluconazole is well established as a leading drug in the setting of prevention and treatment of mucosal and invasive candidiasis. Fluconazole displays predictable pharmacokinetics and an excellent tolerance profile in all groups, including the elderly and children. Fluconazole is a fungistatic drug against yeasts and lacks activity against moulds. Candida krusei is intrinsically resistant to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 235 references

Itraconazoleversus fluconazole forpreventionof fungal infections inpatients receivingallogeneicstem cell transplants

  • MarrKA, CrippaF, LeisenringW
  • Blood
  • 2004
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…